Novel multiple myeloma drug recommended for UK NHS use

Multiple myeloma

The UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the use of Nexpovio (selinexor), in combination with bortezomib and dexamethasone, as a treatment for eligible multiple myeloma patients who have received one or two prior treatments.

The recommendation follows recent NICE guidance recommending Nexpovio, in combination with dexamethasone, for eligible myeloma patients who have had four or more prior treatments.

The guidance states that the drug is recommended for patients who have had one previous line of treatment and who are refractory to both daratumumab and lenalidomide or who have had two previous lines of treatment and are refractory to lenalidomide.

“This decision is a remarkable step forward in addressing significant unmet needs in myeloma,” said Dr Neil Rabin, Consultant Haematologist at University College London Hospitals. “Being able to use different treatments that work in a variety of ways is critically important to help evade and overcome the cancer’s defence mechanisms. Today’s news has enabled just that and means we now have a new way to treat this complex and challenging blood cancer.”

Nexpovio works by restoring some of the body’s anti-cancer defence mechanisms. It does this by blocking the action of protein exportin 1 (XPO1), which takes critical tumour-prevention proteins out of the nucleus where they have little effect.

Rick Coope, General Manager at Menarini Stemline UK, said: “We are incredibly proud that in Menarini Stemline’s first engagement with NICE, we have successfully reached an agreement for two appraisals – and three lines of therapy – in such a short period of time. Now, our focus shifts to obtaining equal access to Nexpovio across the UK and progressing research to bring further innovation to patients with haematological and oncological conditions.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free